Re-thinking pharmaceutical production in Africa:Insights from the analysis of the local manufacturing dynamics in Mozambique and Zimbabwe by Russo, Giuliano & Banda, Geoffrey
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Re-Thinking Pharmaceutical Production in Africa
Citation for published version:
Russo, G & Banda, G 2015, 'Re-Thinking Pharmaceutical Production in Africa: Insights from the Analysis of
the Local Manufacturing Dynamics in Mozambique and Zimbabwe' Studies in Comparative International
Development, vol. 50, no. 2, pp. 258-281. DOI: 10.1007/s12116-015-9186-2
Digital Object Identifier (DOI):
10.1007/s12116-015-9186-2
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Studies in Comparative International Development
Publisher Rights Statement:
This is a post-peer-review, pre-copyedit version of an article published in Studies in Comparative International
Development. The final authenticated version is available online at:
https://link.springer.com/article/10.1007/s12116-015-9186-2]
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
1 
 
Title page 
 
Title: Re-thinking pharmaceutical production in Africa; insights from the analysis of the 
local manufacturing dynamics in Mozambique and Zimbabwe 
 
Authors: Giuliano Russo1,2. *, Geoffrey Banda3 
* corresponding author. grusso@ihmt.unl.pt. 
 
Affiliations:  
1International Health and Biostatistics Unit, Instituto de Higiene e Medicina Tropical, 
Nova University of Lisbon. Rua da Junqueira 100, Lisbon (Portugal) 
2Institute of Development Studies, Library Road, University of Sussex, Brighton, East 
Sussex BN1 9RE (United Kingdom) 
3The Open University. Walton Hall, Milton Keynes, Buckinghamshire MK7 6AA, 
(United Kingdom) 
 
Running head: 
Pharmaceutical manufacturing dynamics in Mozambique and Zimbabwe 
  
2 
 
Abstract 
Until recently consensus existed in certain circles that the African industry was not 
suitable for cost-effective production of quality, safe drugs. Yet public and private 
pharmaceutical enterprises have cropped up on the continent, with some venturing 
into production of sophisticated and complex drugs, such as antiretrovirals (ARVs).  In 
our study we analyse and contrast the dynamics of local pharmaceutical manufacturing 
in Mozambique and Zimbabwe with the objective of understanding why pharmaceutical 
production in Africa is picking up momentum, and the influence of global funding for 
ARVs in this process. Our analysis identifies two routes of development for local 
pharmaceutical manufacturing: a favourable economic outlook and support from the 
international community created the necessary conditions for the development of the 
nascent pharmaceutical industry in Mozambique, while in Zimbabwe the presence of 
an established local industry was instrumental in bringing in favourable, if not always 
coherent, government regulation. In both countries, the introduction of AIDS treatment 
created windows of opportunity for local production of pharmaceuticals by increasing 
public sector demand, providing fresh funds, and providing a justification for 
government regulation favouring local production. Despite the long-standing and well-
known problems that created persistent shortcomings in human resources, as well as 
the economic and industrial environments, we conclude that pre-existing 
developmental roots, international funds and supportive state industrial policies are 
encouraging more manufacturers to enter the business of local pharmaceutical 
production in Africa. However, the opportunities brought in by fresh AIDS funds will 
need to be sensibly managed at both the local and global levels, as the world’s interest 
on the disease may not last in the long term. 
Key-words: Medicines in Africa; pharmaceutical manufacturing; pharmaceutical 
markets; Mozambique; Zimbabwe. 
3 
 
 
1 Introduction 
In this paper we explore the dynamics of pharmaceutical manufacturing in 
Mozambique and Zimbabwe and the impact of the introduction of antiretroviral (ARV) 
treatment on the industry, with the objective of shedding light on an important but still 
understudied topic and contributing to the wider debate on local production of drugs in 
low-income settings. We selected the two countries as they both have attributes that 
make them likely and unlikely candidates for local production, and their distinct political 
economic contexts led to different industrial responses to the same trigger – the AIDS 
pandemic. Zimbabwe has a long history of industrial development, but it has been 
undergoing economic and political crisis for a decade. Mozambique is one of the 
poorest and least developed countries in the world, but it is a darling of international 
donors, and its pharmaceutical sector in particular has enjoyed strong support from 
Brazil. 
By analysing the evolution of the two industries, their progress and setbacks, as well 
as the role played by national governments and international community in the 
process, we aim to offer insights into the possible advantages of local production of 
drugs, the hurdles encountered in setting it up, and the opportunities – as well as 
challenges – presented by the global push for AIDS treatment.  Through our case 
studies we identify one route of development for local pharmaceutical manufacturing 
passing through favourable economic conditions and support from the international 
community, and another taking advantage of an established pre-existing local industry 
and favourable government regulation. In both cases, the introduction of AIDS 
treatment created windows of opportunity for local production of pharmaceuticals by 
increasing public sector demand, providing fresh funds, and providing a justification 
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for government regulation favouring local production. Like the other papers in the 
special issue, the present work aims at closely examining widely held assumptions 
regarding pharmaceuticals and access to medicines in developing countries, in this 
case by examining the debate around local pharmaceutical production in Africa.  
The next section reviews the debates regarding the local production of 
pharmaceuticals in low- and middle-income countries. The following third and fourth 
sections present the two case studies of Mozambique and Zimbabwe, focusing on the 
key changes to these countries’ policies and regulations toward pharmaceutical 
development, changes introduced by ARV production, and hurdles encountered by 
local manufacturers. In section five we contrast the enabling factors and stumbling 
blocks identified across the two settings, and extract lessons for wider debates on local 
production and the effects of the global response to AIDS on the landscape of the 
pharmaceutical sector in Africa. In the sixth section we conclude with a summary of 
our findings and the contributions that our analysis makes to debates on local 
pharmaceutical production in Africa. 
2 Local pharmaceutical production in Africa 
Despite accounting for 25% of the world’s burden of disease (Institute for Health 
Metrics and Evaluation and Human Development Network the World Bank 2013) 
access to medicines in African countries remains limited on account of the 
unavailability of many drugs at affordable prices (Cameron et al. 2009). As Africa 
imports the vast majority of the pharmaceutical products consumed (UNCTAD 2013), 
many take the view that fostering local production could be an effective way to improve 
access to medicines by shortening the supply chain and cutting down import costs, 
and at the same time helping the development of the continent’s industrial complex 
(Chaudhuri, Mackintosh, and Mujinja 2010; UNIDO-AUC 2012). The literature 
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suggests a number of arguments supporting the logic of local production of 
pharmaceuticals, such as: (a) the need for a stable and reliable drug supply to attend 
healthcare goals; (b) the ability to provide for specific local needs; (c) flexibility and 
ability to adapt to a changing epidemiological profile, and; (d) its ability to identify local 
product markets and willingness to distribute outside major urban centres (Shadlen 
and Fonseca 2013; Mujinja et al. 2014). Experiences from Asia and Latin America also 
show that local production of pharmaceuticals can be efficient (Kuanpoth 2007), 
strategic for implementing national health policies (Flynn 2008), and in some cases, 
may end up having global health and industrial repercussions (Waning, Diedrichsen, 
and Moon 2010).  
However, given the dramatic price reductions brought by Asian generic drugs, a 
commonly held view is that, rather than investing in the local industry, focussing on 
world-wide procurement of inexpensive drugs would be a more efficient use of African 
governments’ drug funds (WHO 2011). Others maintain that African countries often 
lack the critical mass of industrial services and human capital required to produce 
quality drugs at competitive prices (Kaplan and Laing 2005), and that local 
manufacturing could do little in the way of reducing the upward pressure on drug prices 
from international patents (Rovira 2006). As also shown by other papers in this special 
issue, to a large extent the AIDS epidemic has come to amplify the terms of the debate 
on pharmaceuticals and the developing world, by compounding its share of the burden 
of disease, demand of high-value products, need of affordable treatment, and 
opportunities to exploit Trade-related Intellectual Property Rights (TRIP) flexibilities 
(Benatar 2004). 
Recent efforts to map out the pharmaceutical manufacturing industry in Africa by the 
African Union - Global UNIDO Project (UNIDO-AUC 2012) and the GIZ project to 
survey manufacturing capabilities in Eastern Africa (GIZ 2012) highlighted how, 
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despite the shortcomings of weak industrial and governance environments, local 
production of pharmaceuticals in Africa has developed progressively since the 1930s, 
with numerous pharmaceutical factories having started operations in Africa, and 38 
countries in the continent presently estimated to have operating pharmaceutical 
manufacturing entities. Although incomplete, fragmented and focussing mostly on 
English-speaking economies, the existing information on Africa’s pharmaceutical 
production capabilities paints a picture of consistent development of the industry, with 
the first local operations by international companies started between the 1930s and 
1960s in South Africa, Nigeria, Zimbabwe and Morocco, followed by a second wave of 
locally-owned companies in Uganda, Nigeria, Kenya, Tanzania and Botswana in the 
1970s and 1980s (Figure 1). 
 
<Insert Figure 1 here> 
 
While the early genesis of local manufacture especially in Nigeria and Zimbabwe was 
linked to multinational firms establishing subsidiaries in colonies, during the later part 
of the 1960s onwards, local entrepreneurs with experience in the multinational 
pharmaceutical companies started setting up their own production facilities. Currently, 
the majority of the existing pharmaceutical manufacturers in Africa are reported to be 
small, locally-owned private companies that primarily serve local markets, although 
larger state-owned enterprises are also being established1. International importers and 
                                               
 
1 Such as Saidal in Algeria and Saphad in Tunisia. 
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distributors are also reported to keep setting up their own plants on the continent or 
entering joint ventures with local manufacturers2 (UNIDO 2010).  
 
The proliferation of pharmaceutical enterprises over multiple countries paints a picture 
of a dynamic manufacturing terrain that has shown pharmaceutical companies rising 
in different geographies, with little comprehensive information on the nature and extent 
of the industry being collected, consolidated and disseminated. A patchwork of mostly 
descriptive studies currently exists on pharmaceutical manufacturing in Africa as well 
as on other low- and middle-income settings; an analysis and comparison of such 
diverse experiences is what appears to be missing, identifying commonalities and 
possible paths to development. Our paper sets out to fill this gap by analysing and 
contrasting the dynamics of pharmaceutical manufacturing in Mozambique and 
Zimbabwe, with the objective of contributing to the current understanding of why 
pharmaceutical production in Africa is picking up momentum, and the influence of 
global funding for ARVs in this process.   
3 Pharmaceutical manufacturing in Mozambique 
Mozambique is a low-income country (LIC) ranking 185th out of 187 in the United 
Nations Human Development Index. Having achieved independence from Portugal in 
1975, Mozambique experienced 16 years of civil war that profoundly affected the 
country and its health care system. Following the 1992 Rome peace accords, these 
days Mozambique is rapidly developing, thanks to substantial Overseas Developing 
                                               
 
2 For example CIPLA and Quality Pharmaceuticals in Uganda. 
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Assistance funds first, and then by the recent discovery of natural resources. However, 
the recent economic growth has exacerbated socio-economic differences, fuelling 
discontent on the government’s less-than-ideal record on governance (Fairbairn 
2013). With an average health spending of just USD35 per capita, the Mozambican 
health care system finds itself under continued pressure because of population high 
mortality and morbidity rates, not least because of the HIV/AIDS infection  (Table 1).  
 
<Insert table 1 here> 
 
Mozambique’s post independence pharmaceutical policy was praised as one of 
Africa’s most progressive, as its cash-strapped Government, heavily dependent on 
foreign aid and drug imports, adopted a strict essential drugs list approach, 
nationalised procurement and distribution, and focussed on generic drugs to extract 
the best possible value from its drug budget (Barker 1983). In the last decade 
Mozambique has become one of the world’s largest recipients of health aid funds (Van 
de Maele, Evans, and Tan-Torres 2013), with international drug funds managed first 
through an externally-managed Drugs Common Fund (Pavignani and Durão 1999), 
and subsequently through an MoH-managed Sector Wide Approach common fund 
agreement (PROSAUDE). With the global push for AIDS fight and the introduction of 
Antiretroviral Treatment (ART) in 2003, the country started benefitting from a 
considerable injection of AIDS funds, with Antiretroviral drugs procured in the 
international market by organisations like the Global Fund, the World Bank and USAID. 
Such drugs are imported in kind to the country to be distributed by the Ministry of 
Health through its system and to foreign AIDS Non-Governmental Organisations, 
despite the scarcity of pharmaceutical skills and the absence of an updated National 
Pharmaceutical Policy. The soon to be approved national plan to scale up ART aims 
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at taking advantage of donors’ profligacy for this area and provide treatment to 80% of 
the infected. 
Local production of pharmaceuticals is nascent in Mozambique, as only 1 producer 
exists, having started production in 2013 with support from the Brazilian government. 
The market is currently dominated by the public sector that imports drugs through the 
MoH Central Drugs and Medical Supplies Agency (CMAM) and by a highly 
concentrated group of private importers/wholesalers selling to a retailing network of 
264 private pharmacies, 40 publicly owned retailers, and occasionally to CMAM. 
The pharmaceutical market in Mozambique was estimated to be worth approximately 
USD140 million in 2012 in terms of the value of drugs imported (COWI 2012), which 
represented a drug expenditure of USD5.55 per capita. Approximately USD 122 million 
(85%) of the total market value was represented by public sector imports, the vast 
majority of which was funded by external funds and donations, some of them managed 
by the local Ministry of Health (MISAU) through the sector budget support fund - 
PROSAUDE (CMAM 2011). Between 2004 and 2012 public drugs expenditures went 
from USD 78 million to 122 million, the increase being driven by in-kind AIDS drugs 
donations, that went from the original USD4 million to the current 49 in eight years 
(COWI 2012). 
 
<Insert table 2 here> 
 
AIDS drugs expenditures were the single largest budget item in 2012, representing 
40% of all the public sector drugs, and were imported into the country exclusively as 
in-kind donations managed directly by the responsible international organizations. 
State Budget funds contributed to 18% of the overall public sector drug expenditures, 
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while North-America-based organizations (USAID and the Clinton Health Access 
Initiative – CHAI) contributed to import 68% of all the AIDS drugs in the country. 
 
<Insert table 3 here> 
 
Little consolidated data exists about the private pharmaceutical market, with some 
estimates putting it at approximately USD 20 million, calculated on the basis of the 
drugs value declared on the import documents submitted to the pharmaceutical 
department in 2012 (COWI 2012).  Currently, although 54 private importers are 
officially registered in Mozambique, the private sector is highly concentrated, with the 
4 largest firms covering above 50% of the drugs imported (Medis, Maputo Healthcare, 
Generics and Specialties, and Welworth). Of the 2,572 pharmaceutical products 
currently registered for importation by private operators in Mozambique, 55% are of 
Indian origin, followed by 12% of drugs from Portugal and 5% from Brazil and Germany 
(COWI 2012). 
3.1 Regulation of the sector 
Regulation of the sector is based on the 1996 Pharmaceutical Sector Strategic Plan 
(MISAU 1996). The MoH’s Pharmaceutical Department (recently re-named Hospital 
Pharmacies Directorate) is in charge of the regulation of the sector, supported by the 
Inspection Directorate and the National Laboratory for Drugs Quality Control (LNCQM) 
and advised on specific pharmacological issues by the Therapeutic Technical 
Commission, an unelected body composed of notable physicians from the Maputo 
Central Hospital. All drugs entering the country are required to seek registration with 
the Pharmaceutical Department; since little capacity exist within LNCQM for laboratory 
analysis, as in many other African countries, the Drug Registration System is the main 
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tool to guarantee the quality of the imported drugs, and individual importers are 
responsible and held accountable for the quality of the drugs they import. No 
bioequivalence standards exist for generics; inspectorate reports and anecdotal 
evidence suggest that, although safety is not an issue, the quantity of active substance 
in drugs available in the Mozambican market can be diverse, especially across non-
branded generics from less well-known Indian manufacturers (Russo and McPake 
2010).  
CMAM is responsible for planning, procuring and distributing drugs for the public 
sector. CMAM typically uses limited open tender procedures to procure drugs locally 
as well as internationally; by law, bids by national providers are given preference as 
long as their price does not exceed 15% of the cheapest competing international bid 
(COWI 2012). Local suppliers are often resorted to in case of emergencies and 
(frequent) drugs stock-outs, in order to shorten the regular drug acquisition cycle, 
estimated to last in excess of 265 days, depending on the type of funds used. In a 
move to promote national production, primary chemical products – such as 
pharmaceutical Active Pharmaceutical Ingredients (APIs) – have been exempted from 
import duties (de Oliveira 2013). 
In theory, the private sector has been regulated by quality, profession and price 
legislation since the 1990s, but in practice, even such less-than-detailed regulation has 
not been substantiated by real enforcement. Privately imported medicines are licensed 
and registered by the Pharmaceutical Department, and are subject to chemical 
analysis by the National Medicine Quality Control Laboratory. MISAU regulation 
establishes pharmacy venues and warehousing standards, and pharmacies are 
subject to internal inspections. Prices are regulated through a cost-plus system fixing 
cost and profit mark-ups for each stage of medicine distribution (Government of 
Mozambique 1990, 1998, 2003). A recent study showed that private operators often 
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disregard such mark-ups and profit margins, given MoH’s limited enforcement capacity 
(Russo and McPake 2010). 
In the last decade the sector has tried unsuccessfully to reform its drug registration 
and pricing systems (Russo and McPake 2010), with the objective of increasing the 
quality of the drugs imported, and expanding the range of drugs available in the 
country. Despite a recent botched attempt to reform profit margins and mark-ups (GoM 
2010), strongly resisted by both private importers and local distributors, at the time of 
writing, the private sector pricing regulation in force is still that dating back to 1990. 
3.2 The SMM’s experience 
Mozambique’s Pharmaceuticals Limited (Sociedade Moçambicana de Medicamentos, 
SMM) is a public enterprise set up on the outskirts of Mozambique’s capital city to 
locally manufacture pharmaceuticals with the financial and technical support of the 
Brazilian cooperation. The Brazil-Mozambique collaboration started in 2003 after an 
agreement between former presidents Lula and Chissano, and was developed during 
the last decade as a ‘South-South’ cooperation project, seeing the involvement of 
multiple Brazilian and Mozambican players and going through a number of political, 
international relations and industrial processes (Russo, Cabral, and Ferrinho 2013). 
The original agreement had the stated objectives to: (a) expand the population’s 
access to ART in the country; (b) build local production of generic pharmaceuticals; (c) 
reduce dependence on international pharmaceutical imports, and; (d) contribute to 
building local pharmaceutical capacity in Mozambique (de Oliveira 2013). The 
Government of Brazil (GoB) committed to providing funds for staff training and capacity 
building, equipment, technical assistance, raw materials, design of the factory and 
management; the Government of Mozambique took responsibility to purchase the 
infrastructure for the factory, to undertake rehabilitation works, and for the factory’s 
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recurrent expenditures, including local staff’s salaries, and to purchase drugs from 
SMM.  
The Oswaldo Cruz Foundation (Fiocruz) - Brazil’s leading public health institution – 
conducted the factory’s feasibility study in the three following years, and, after 
negotiating the financial support of VALE – a Brazilian mining company with operations 
in Mozambique – infrastructure works were finalised in 2012. Farmanguinhos – 
Fiocruz’s pharmaceutical arm – donated equipment, pharmaceutical production 
technology files and technical assistance, and production of Nevirapine, Lamivudine, 
Captopril and Hydrochlorothiazide started in 2013 (Russo et al. 2014). 
So far, SMM is the only pharmaceutical factory in Mozambique, as premises and 
equipment of the previous existing factory was purchased to make space for SMM’s 
operations. The Government of Mozambique’s State Shareholding Management 
Institute (IGEPE) owns the factory project, while the chair of its administrative board is 
appointed by MISAU, as is the executive director of the factory. 
SMM is located in the Greater Maputo Area on a 20,000-m2 allotment close to the 
capital’s commercial port and to the South African border. The factory currently 
operates two production lines, one devoted to hospital drippings and other large 
volume liquid pharmaceutical compounds, and the other to solid compressed 
pharmaceutical compounds. According to its business plan (SMM and Farmanguinhos 
2013) the factory will produce 17 different pharmaceutical items including 6 
Antiretroviral products (ARVs) with an annual production capacity of 226 million units 
of ARV and 145 million units of other medicines (see the full list in Annex I). SMM will 
engage in both secondary and tertiary pharmaceutical production (that is, large-scale 
processing of finished pharmaceutical compounds and packaging and labelling 
imported drugs, respectively), without directly producing APIs (which is defined as 
primary production). 
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The factory’s staff requirements amounts to 88 full-time workers (24 for direct 
production, 4 for quality control-related services, and 18 for management and 
administration); at the time of writing only 70 personnel had completed their training 
and had been recruited, and the 2 most senior technical managers were Brazilian 
cooperation staff. In terms of equipment, 18 high-tech pieces have been procured 
internationally and donated by the Brazilian cooperation. 
According to the factory’s business plan, SMM should be able to sell its products at 
prices comparable to those from the international market thanks to savings in the initial 
investment in infrastructure and equipment – donated by the Brazilian cooperation – 
in national transport charges and taxes – particularly favorable to business in 
Mozambique since the original tax rate on chemical products was scrapped. In 
comparison to the typical cost structure for ARVs (Pinheiro et al. 2006), SMM’s 
production costs will be largely driven by Active Pharmaceutical Ingredients’ (APIs) 
imports, and less by taxes, profit margins, research and development and local 
production mark-ups (SMM and Farmanguinhos 2013).  Despite the expected savings 
in local production costs, dependency on the volatile global market for APIs is 
recognized to be a liability for SMM. 
Factory’s sales forecasts predict that, given the installed capacity and under the 
assumption of sustained low local costs and continued Brazilian support, in the next 
three years SMM should be able to put on the market approximately six million USD 
worth of drugs, which should turn the enterprise sustainable by the fifth year of 
production (SMM and Farmanguinhos 2013). As things stand, the national public and 
private markets represent the factory’s customer base, but the wider Southern Africa 
pharmaceutical market should be targeted once all the necessary international quality 
certifications are obtained (COWI 2012). However, despite the optimism of these 
predictions, as the largest proportion of the factory’s output is expected to be sold to 
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the NHS, MISAU’s commitment to absorb SMM’s production will be crucial for the 
financial success of the enterprise.  
3.3 Identified bottlenecks for pharmaceutical manufacturing in Mozambique 
The analysis of the SMM experience shows that pharmaceutical manufacturing is 
kicking-off in Mozambique thanks to the Brazilian and Mozambican government 
support, but the reluctance of private investors to get into this business area signals 
the presence of numerous issues hampering the development of a local 
pharmaceutical industry. 
Human resources were identified as the single most important bottleneck for SMM 
development, as of the 88 staff considered essential to run the factory’s operations, 75 
had to be sent for training abroad, some of the pharmacists currently employed are at 
risk of being poached by competing businesses in wholesaling and retailing, and senior 
executive positions are still covered by expatriate staff. As pharmacy degrees have 
been offered by local university for relatively little time, no pharmacological technology 
specialization exists in the country as yet, and a cap of 5% in the proportion of a 
company’s foreign staff has been imposed by the Government, a medium to long term 
investment in training local staff abroad appears as the only way for the industry to 
recruit the specialists cadres needed to carry out technical tasks. Although personnel 
with middle-management skills seem to be already supplied by the Mozambican labor 
market, experienced executives with a track record of senior management in 
comparable industries are acutely lacking in Mozambique, given the country’s 
relatively recent history of industrial development. 
Mozambique’s industrial environment was also recognized as another factor 
hampering the development of the Brazilian sponsored pharmaceutical factory. 
Consistent with the literature on pharmaceutical manufacturing in Africa (Kaplan and 
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Laing 2005), Mozambique seems to be lacking a ‘critical mass’ of suppliers, products 
and services needed for the development of a competitive business. In SMM’s specific 
case, all the primary products for the transformation of compounds are imported from 
Brazil, and all the basic maintenance and technical services are contracted to South 
African firms, adding on in terms of costs and delays to the production lines.  For the 
SMM case, the option to resort to lower-cost Indian and Chinese equipment had to be 
set aside, given the limited equipment maintenance services provided by such 
suppliers in Africa. SMM’s APIs come subsidized by Brazilian suppliers, which only 
transform the original chemical products imported mostly from India, and in part from 
China – the so-called secondary production. Some pharmaceutical importers in 
Mozambique have resorted to ‘downstream vertical-integration’ of their business to the 
retailing level, in order to benefit from a leaner production chain and from the regulated 
profit margins associated with each distribution stage, while at the same time 
minimizing the risk associated with having to rely on an uncertain industrial 
environment (Russo and McPake 2010).  
Despite the country’s favorable regulation of chemical imports’ tax and duties, 
governance was reported to be a key hurdle for the long-term development of 
pharmaceutical manufacturing in Mozambique. The Government’s ineffective quality 
control of pharmaceutical manufacturing processes and final products may allow de 
facto the employment of cheaper substandard machinery in pharmaceutical production 
and the presence on the market of substandard generic products. Despite cutting costs 
and bureaucracy, the Government’s failure to implement quality controls is pushing 
local suppliers towards the lower end of the pharmaceutical market, where costs and 
prices need to be low to face off international competition. Lack of effective quality 
regulation is believed to benefit those importers of non-branded generics for whom an 
ability to cut costs and offer wildly discounted generics represents the core of their 
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market strategy in Mozambique. Together with the high risk of the local business 
environment, with bank loans’ typically high interest rates, the loose protection of 
property rights and the poor governance typical of the country, contributes to turning 
pharmaceutical manufacturing unpalatable for most entrepreneurs in Mozambique. 
Finally, the local funding environment still represents a critical limitation for 
pharmaceutical production in Mozambique. Given people’s limited ability to pay and 
the lesser size of the private sector, selling to the public sector is the only way for local 
producers to go to scale and access a market worth in excess of USD140 million in 
Mozambique. However, as public purchase of drugs is overwhelmingly funded by 
international donors – either through sector budget support or in kind donations, as in 
the case of ARVs – large international tenders tend to be the norm for the acquisitions 
of public sector drugs. As a result, local producers are left with limited chances to tap 
into a demand for pharmaceuticals that is typically met by free donations, or by 
purchases from the world’s most efficient producers. 
4 Zimbabwe’s pharmaceutical sector 
Zimbabwe is a land-locked southern African country bordered by South Africa, 
Botswana, Mozambique and Zambia.  It has a population of 13.7 million and among 
the world’s worst health indicators (Table 1).  The country’s public health delivery 
system is structured to serve the populace at local, district, provincial and national 
health institutions through a referral system. As at 2012, Zimbabwe had an HIV/AIDS 
prevalence of almost 15% (1.4 million people infected with HIV) down from 32% 
recorded at the height of the HIV/AIDS epidemic.  
Having attained independence and democracy in 1980, Zimbabwe went through a 
decade of a state-managed economy to accelerate development, unlock its economic 
potential and address equity issues. The decade commencing from the 2000s saw a 
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deterioration of the country’s economic conditions, fuelled by hyperinflation and 
international economic sanctions (Brett 2005). Only after 2008 did Zimbabwe’s GDP 
go back to positive growth rates, following a political power-sharing agreement and the 
easing of international sanctions (World Bank 2013).  
Since independence the government took a primary care as well as industrial 
development approach in the organization of its health care services. The 1987 
National Drug Policy (NDP) contained provision to promote the use of generic drugs 
in both public and private sectors and elaborated an Essential Drug List for Zimbabwe 
(Turshen 2001). The NDP also established a Regional Medicines Quality Control 
Laboratory (Froese 1991); a fresh NDP was elaborated in 1999 promoting local 
manufacturing of essential drugs, as well as local research and development and 
technical collaboration within the region, and to the present days Zimbabwe is one of 
the few African countries with an effective drug quality control system (UNIDO 2011). 
Because of the increase in AIDS prevalence, in 2002 the government invoked Trade 
Related Intellectual Property Rights flexibility and issued compulsory licenses to local 
pharmaceutical operators to manufacture and import generic AIDS drugs.  A national 
AIDS Levy was introduced in 2006 to fund the purchase of ARV in local currency. By 
2003 international donations by the Global Fund and the Presidential Aids Relief 
Initiative started importing internationally procured ARVs with WHO or Food and Drug 
Administration quality certifications (UNIDO 2011). 
Zimbabwe’s 2013 allocated annual health expenditure was US$381 million, 
representing 10% of total national expenditure. As much of the initially allocated budget 
does not get spent on drugs, and a considerable share of international drug donations 
fail to appear in the official budget books, many health professionals and policy makers 
consider the system as substantially funded through bilateral and multilateral donors.  
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Official World Bank statistics refer to a USD85 health expenditure per capita for 2012 
(World Bank 2013). 
Business Monitor International estimates that pharmaceuticals expenditure for 2013 in 
Zimbabwe was US$ 223 million up from US$ 203 million in 2012 (BMI, 2009); generic 
drugs constituted 68.5% of the total drug market in Zimbabwe and over the counter 
segment came in at 22.5%. Healthcare spending was forecasted to increase from 
US$220 million in 2009 to US$650 million by 2014.  Government in 2012 allocated for 
medical care services (inclusive of drugs supply) US$63.3 million. Availability of 
essential drugs was estimated to range between 29–58%, and other essential drugs’ 
availability ranged from 22–36% compared to a national target of 75–80% (National 
Budget, 2012).   
Zimbabwe has historically enjoyed some self-sufficiency in drug supply  (Turshen, 
2001), and at that time larger scale pharmaceutical production was targeting the larger 
Central African Federation and exports into the rest of Africa. The industry claims to 
be able to supply 122 products out of the 260 essential drugs for Zimbabwe; 46% of 
the country’s essential drugs (UNIDO, 2011b and NECF, 2011).  When new product 
development initiatives underway are factored in, local drug provision can rise to 75% 
of essential drugs and contribute 5% to GDP (NECF, 2011).  However, currently the 
local industry is not supplying as much drugs to the public health systems as in the 
past.  Table 4 below shows how dependent the country has been on pharmaceutical 
imports from 2006 to 2011.  Pharmaceutical imports increased from US$ 39.2 million 
in 2006 to US 89.4 million in 2011 reflecting low industrial capacity utilisation caused 
by hyperinflation, shortage of foreign currency and infrastructural failure.   
 
<Insert table 4 here> 
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Procurement of drugs in general for the public health system is managed by Natpharm 
using funds from the health budget and Natpharm’s own resources, however approval 
by the State procurement board is required for tenders.  There are private sector 
distribution agents/wholesalers who sell mainly to private hospitals and pharmacies 
(ZPCP, 2011).  However procurement of ARVs, especially for Global Fund 
programmes, is done through international tenders through the UN pooled 
procurement by UNICEF, as UNDP is the principal recipient of the funds in Zimbabwe.  
The National Aids Council (NAC) manages the procurement of drugs using funds 
raised through the AIDS levy.  Other multi-lateral and bilateral donors use their in-
house procurement vehicles and procure drugs mostly from outside the country. 
Funding for ART (anti-retroviral treatment) programmes in Zimbabwe in some respect 
received extra attention from government and the donor community alike. The 
government of Zimbabwe enacted the National Aids Council (NAC) Act in 1999, which 
gave rise to the National Aids Trust Foundation entrusted with administering the AIDS 
levy.  The primary local source of funding for the antiretroviral treatment programme in 
Zimbabwe is the AIDS levy.  The AIDS levy was initially set up as a drought levy by 
the government to raise funds to mitigate the effects of drought in the country.  When 
HIV AIDS became a challenge this drought levy was converted into an AIDS levy 
through government legislation by the Ministry of Finance.  The government collects 
3% tax from all formally employed people and the funds are allocated to NAC through 
the National Aids Trust Fund (NATF).  The requirement set by government is that 50% 
of the resources must be used to procure drugs for HIV/AIDS related illnesses. 
After pegging the local Zimbabwean dollar to a basket of international currencies, the 
Aids levy has contributed significantly to the ART programme supporting 24 per cent 
of patients on ART in 2010. The bulk of funding however came from Global Fund 
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(35%), USA government (18%) and the Extended Support Programme that was led by 
DFID of UK (22%).  Collections for the NAC for 2010 were US$ 39.9 million; made up 
of US$ 20.5 from AIDS levy and US$ 18.7 million from donors.  Of the US$ 20.5 million 
from the AIDS levy, 50% is required to be used for drug procurement. 
Collection of the AIDS levy in the era after dollarization of the Zimbabwean economy 
rose to US$ 32.5 million from a base of US$ 5.7 million in 2009 (Table 5), and based 
on the 2006 Government policy, 50% of the AIDS levy was allocated to ARV drug 
procurement.  NAC procured ARV medicines valued at US$ 18.5 million in 2012 up 
from the previous year’s US$ 5.2 million (NAC, 2012).   
 
<Insert table 5 here> 
 
However, the bulk of HIV/AIDS funding has historically come from the bilateral and 
multilateral donor community and total expenditures were US$ 35.4 million (2007), 
US$ 25 million (2008) and US$ 37.8 million (2009) (UNGASS report, 2009). Fifty per 
cent of the AIDS levy goes towards treatment and ARV drug procurement 
progressively increased from US$ 0.89 in 2009 to US$ 18.6 million in 2012 (Table 5).  
Expenditure on ARVs of US$ 18.6 million implies a viable local market for the local 
pharmaceutical industry to support; if they can produce competitively ARVs needed 
for recommended treatment regimens in Zimbabwe. 
4.1 The pharmaceutical industry in Zimbabwe 
The pharmaceutical industry in Zimbabwe dates back to 1953 driven by the country’s 
early industrial development. In 1990 Zimbabwe was, after South Africa, touted as the 
African country with potential to become the next newly industrialising country because 
of its established and vibrant manufacturing sector. However the pharmaceutical 
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industry currently concentrates on secondary and tertiary production only, and there 
are currently no subsidiaries of large multinational pharmaceutical companies 
operating manufacturing plants in Zimbabwe (UNIDO, 2007, 2011b).  There are 
currently nine pharmaceutical manufacturing companies registered with the Medicines 
Control Authority of Zimbabwe (MCAZ), and of these, five, are the major generic 
manufacturers accounting for 90% of the formulation businesses (UNIDO, 2011b).  
According to Seiter’s (2005) classification, Zimbabwean pharmaceutical companies 
fall into the category of generics companies with predominantly national operations 
and small-to medium scale local manufacturers limited to formulation development, 
production and packaging activities.  These local generics manufacturing companies 
operate in a competition intensive, low margin, commodity-type business, where 
profitability and long-term viability depend on economies of scale, assured demand 
and large markets (Berger et al., 2009; Kaplan and Laing, 2005).   
Zimbabwean pharmaceutical companies by the early 2000s (prior to the onset of the 
economic downturn) were exporting pharmaceutical drugs to South Africa, Zambia, 
Namibia, Malawi, Tanzania, Burundi, Rwanda, Botswana, Democratic Republic of 
Congo, Mauritius, Kenya, Uganda and Mozambique. The companies had registered 
products in Kenya, Tanzania, Malawi, Zambia, Mozambique, Lesotho, Swaziland, 
Namibia, Uganda and South Africa (UNIDO 2007).   
The medical regulatory authority that oversees the pharmaceutical manufacturing 
industry is the Medical Control Authority of Zimbabwe (MCAZ).  MCAZ is responsible 
for pharmaceutical surveillance, licensing, enforcement, laboratory services, 
evaluation and registration activities for the sector. 
From a human capabilities perspective, the pharmaceutical industry is supported with 
engineering, chemistry, microbiology and pharmacy graduates from local universities 
and polytechnics.  Zimbabwe used to have a robust technical training policy through 
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the polytechnics that was funded by the Zimbabwe Manpower Development Fund 
(Zimdef); students were supported through university by government loans and grants.  
The school of pharmacy critical to supplying pharmaceutical research and 
development as well as production skills was established in 1974 as a department 
within the College of Medicine at the University of Zimbabwe and has played a major 
role in strengthening human capabilities in the local industry in spite of brain drain for 
the last fifteen years. 
4.2 ARV manufacturing in Zimbabwe 
Zimbabwe’s pharmaceutical industry has long been capable of manufacturing drugs 
locally, and the country was one of the first African countries to use the compulsory 
licensing route to effect local production of ARVs for public use to address the 
HIV/AIDS pandemic (Osewe, Nkrumah, and Sackey 2008). In 2002 the government of 
Zimbabwe declared an HIV/AIDS state of emergency, and invoked section 35 of the 
Zimbabwean patents act, which authorises a third party to manufacture and sell 
products (Sacco 2004). Thus the government in 2002 issued the General Notice 240 
of 2002, which allowed local production, use and import of any patented drug including 
any antiretroviral used in the treatment of persons suffering from HIV/AIDS or any 
HIV/AIDS related conditions3.  The initial state of emergency was for 6 months, which 
                                               
 
3 General notice 240 of 2002; “2. In view of the rapid spread of HIV/AIDS among the population of 
Zimbabwe, the Minister hereby declares an emergency for a period of six months, with effect from the 
date of promulgation of this notice, for the purpose of enabling the State or a person authorised by the 
Minister under section 34 of the Act (a) to make or use any patented drug, including any antiretroviral 
drug, used in the treatment of persons suffering from HIV/AIDS or HIV/AIDS related conditions; (b) to 
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was extended for a further for five years up to 2008. On the 8th of April the Minister of 
Justice wrote a letter to Varichem Pharmaceuticals (Pvt) Ltd authorising them to 
produce ARV or other HIV/AIDS related drugs and to supply seventy five per cent of 
their production to the state (Osewe, Nkrumah, and Sackey 2008).  The country’s use 
of the compulsory route in 2003 is believed to have spurred local manufacture of ARVs 
thereby demonstrating political will and deployments of a policy infrastructure that 
promoted local pharmaceutical manufacturing (UNIDO 2011). 
Four Zimbabwean pharmaceutical companies registered twenty generic ARVs with the 
Medicines Control Authority of Zimbabwe (MCAZ); Varichem (13), CAPS (4), Datlabs 
(1) and Plus 5 pharmaceuticals (2) (UNIDO, 2011b).  However, only Varichem is 
currently manufacturing ARVs and it is the sole supplier of locally manufactured ARVs 
(UNIDO, 2007, 2011b). Varichem is also the only Zimbabwean local pharmaceutical 
company holding the WHO pre-qualification accreditation, and there has been growing 
concern at the multiple accreditations that African pharmaceutical companies need to 
meet and the concomitant cost of that regulation.   
ARVs manufactured in Zimbabwe are predominantly first line treatment drugs falling 
under the broad classification of nucleoside reverse transcription inhibitors; Zidovudine 
(AZT, ZDV), Lamuvidine (3TC) and Stavudine (d4T), with Tenofovir (TDF) under 
                                               
 
import any generic drug used in the treatment of persons suffering from HIV/AIDS or HIV/AIDS-related 
conditions”.  Source:  http://www.wipo.int/wipolex/en/text.jsp?file_id=214688 accessed 25 February 
2014 
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development for both adult and paediatric formulations. For the non-nucleoside 
reverse transcription inhibitors, only Nevirapine (NVP) is manufactured in Zimbabwe, 
whilst Efavirenz (EFZ) is under formulation development. In the protease inhibitors 
class Indinavir (IDV) is the only ARV manufactured locally. As a consequence, local 
pharmaceutical manufacturers cannot compete for tenders that include ARVs currently 
not produced in the country, which is basically for all second line treatment drugs.  The 
greater proportion of ARVs for the antiretroviral treatment (ART) programme in 
Zimbabwe, are imported from Indian companies such as Matrix, Ranbaxy, Cipla, 
Aurobindo and Hetero. 
In 2008, local production capacity was 1.15 billion tablets and capsules, and local 
production benefitted from government procurement through special dispensations of 
supplying the public health sector without going to tender (Osewe et al, 2008).  
Government showed commitment by procuring the greater portion of ARV supplies 
from Varichem, and there was a price reduction as prior to local manufacture costs of 
drugs per month were US$ 30 and when local production came on stream Varivar sold 
at US$15 per month (Osewe et al, 2008).  
4.3 Identified bottlenecks for pharmaceutical manufacture in Zimbabwe 
In Zimbabwe’s case, the existing studies identified key structural policy and practice 
hurdles hampering the growth of local pharmaceutical production, such as the need 
for technological capability improvement and innovation take off.  Access to finance, 
finance capability (Banda, 2012), reduced drug procurement capacity by the public 
system, policy incoherence (health versus industry policy), and an unreliable supply of 
basic production inputs such as electricity and water, were named as key 
manufacturing bottlenecks..   
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Studies by UNIDO (2007; 2011), and Banda (2012) found out that lack of access to 
finance - especially long term finance ,as well as access to foreign currency to pay for 
key imports have been hampering local pharmaceutical production for over two 
decades.  The shortage of foreign currency due to balance of payment deficits has had 
a negative impact on the provision of foreign currency denominated loans by local 
financial institutions.  Coupled with a short-term focus to lending by local financial 
institutions, pharmaceutical companies have not had local financial support for capital 
investment financing (Banda 2013).  As a result, Zimbabwean pharmaceutical 
companies have come to depend on internally generated funds to finance acquisition 
of plant, equipment and machinery, hampering innovation as well as the swift 
replacement of old machinery leading to inefficiencies and loss of competitiveness, 
while Indian pharmaceutical competitors have access to concessionary loans and 
export incentives. 
Others reported that the main infrastructural hurdle faced by Zimbabwean local 
pharmaceutical companies are access to good potable water at high pressure to feed 
the reverse osmosis plants and intermittent supply of electricity (Banda, 2013), with 
companies resorting to sinking boreholes and installing standby generators to ensure 
consistent supply of water and electricity to the plant. 
The economic instability experienced after the foreign-designed economic structural 
adjustment programme and high inflation have constrained government’s financing 
ability for the public health system.  This culminated in the collapse of the public health 
system between 2003 and 2009, and in high donor-dependence for financing public 
health systems and drug procurement (Managing Director Pharmaceutical Company 
B, 2011).   
Policy incoherence has often been highlighted as an unhelpful factor for local 
pharmaceutical manufacture. Imports of finished ARV drugs into Zimbabwe are to date 
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duty-free, but excipients and other consumables with common use for the production 
of key drugs, are still subject to duty payment.  When a compulsory licence was issued 
to Varichem, the government promised to purchase at least 75% of the ARVs produced 
locally; however when public funds became limited as inflation set-in, local 
procurement for the public health system declined, compromising the national 
manufacturing industry.   
More recently, however, many observers have identified a policy shift towards 
supporting local manufacture of drugs.  These days funds raised nationally can only 
be applied to buy locally-produced products – in the specific AIDS case, only for first 
line treatment ARVs.  However as public pharmaceutical procurement is still critically 
dependent on external international grants, the government’s discretionary power to 
buy locally is limited; the bulk of ARVs for donor-supported antiretroviral treatment are 
still imported through in-house institutional procurement vehicles, while ARVs for 
Global Fund-sponsored programmes are procured internationally by UNICEF, who is 
not inclined to source drugs in Zimbabwe.  
The UNIDO reports also point out that generally pharmaceutical skills, human 
resources and lack of WHO certification are also key challenges for the industry.  
However, what Banda (2013) identified was that, while local skills for pharmaceutical 
production and quality assurance are still available in the country – including for 
technical positions in analytical chemistry and microbiology -, what seems to be lacking 
are experienced managers who could for spearhead national pharmaceutical research 
and development activities.  
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5 Determinants for the development of pharmaceutical production 
capacity in Mozambique and Zimbabwe 
From the comparison of the two experiences, two models of development of local 
pharmaceutical capacity appeared to emerge; one based on established industrial 
institutions, actively supported by favorable state industrial policies in Zimbabwe, and 
the other supported by the international health community, supported by the 
government’s business interest in developing a national pharmaceutical industry in 
Mozambique (Table 6).  
Three aspects appeared to differ substantially in the two countries and critically 
influence the dynamics of local pharmaceutical production: (a) the economic situation; 
(b) the role of the international health donors, and; (c) the presence of an established 
local industry calling for favorable government regulation. On the one hand, 
Mozambique has experienced sustained growth in the last decade that spurred internal 
consumption and improved supply conditions. The economic outlook for the country is 
even more optimistic, as the recent discovery of natural resources hints at a future of 
double-digit growth for the next five years (World Bank 2013). On the other hand, 
Zimbabwe’s economy has only recently come back to growth after a decade of falling 
GDP, which is believed to have had a long-term negative impact on local human 
capital, business environment and access to capital and to foreign currency (Banda 
2013). 
In the Mozambican case, the politics of South-South cooperation, drive and support 
from the international aid community were key determinants for establishing and 
grooming the only pharmaceutical factory in the country, both because of the role 
played by the Brazilian Technical Cooperation, and because of the vast international 
funds that have contributed to public purchase of pharmaceuticals since the 1980s 
(Barker 1983). Since the peace accord, Mozambique has been one of Africa’s largest 
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recipients of health aid (Van de Maele, Evans, and Tan-Torres 2013), even to these 
days of natural resources-fuelled economic growth. The mining industry’s interest have 
been claimed to be also behind Brazil’s support to Mozambique’s social sectors (Portal 
Vermelho 2010). Against such an economic backdrop, the Government of 
Mozambique is getting behind the national industrial development – perhaps driven by 
self-interest as many politicians happen to have personal involvement in State 
businesses – from directly participating in public production of pharmaceuticals, to 
agreeing to purchase the bulk of local output, to introducing duty exemptions for APIs 
and equalization preference to boast competitiveness of locally produced products. 
 
<Insert table 6 here> 
 
In Zimbabwe, the existence of a consolidated and diversified local pharmaceutical 
industry capable of producing nearly half the items in the national formulary, as well as 
the government’s capacity to control quality of products in the market, were pointed 
out as factors affecting positively the industry’s dynamics. In such a context the 
government also introduced favorable legislation for the local industry, such as 
compulsory licensing for the production of AIDS-related drugs in Zimbabwe, and the 
AIDS levy to finance the acquisition of drugs with locally-raised (and presumably more 
flexible funds). However, with the deterioration of the economic conditions, 
government’s industrial policies have not been consistently supportive of the local 
industry, as a string of import duties and value added tax still contribute to turn locally-
produced drugs uncompetitive vis-à-vis internationally produced ones.  
To some extent, the AIDS epidemic and the introduction of Antiretroviral Treatment 
has come to change the pharmaceutical landscape in the two countries, as these have 
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(a) brought on a renewed interest in cheaper production of drugs; (b) attracted new 
international players and funds, and; (c) provided a new rationale and justification for 
government intervention in the pharmaceutical area.   
Drugs have always been a crucial component of the health systems and health 
expenditures in the two countries. However, the global push for universal access to 
AIDS medicines has come to raise the interest around how drugs are produced, 
administered and priced. In Mozambique, although only 6 of SMM’s product portfolio 
are ARVs, the factory is widely known as ‘the ARVs factory’. Without the AIDS focus it 
seems reasonable to presume that no Brazilian-Mozambique pharmaceutical 
collaboration would have come into being, not least because of Brazil’s specific 
expertise in the AIDS fight and the sense of urgency brought in by the epidemic in 
Southern Africa. In Zimbabwe the high HIV/AIDS prevalence rates of the nineties and 
the availability of relatively cheaper drugs from India, created the opportunity for some 
international donors to ‘overrun’ the economic sanctions and aid freeze, but also for 
the government to issue compulsory licenses to local producers to manufacture locally. 
These renewed interests in AIDS drugs brought in fresh resources in both countries 
and a new player in Mozambique that would have not entered the pharmaceutical 
arena had it not been for the AIDS epidemic. Already one of the largest health sector 
donors in Mozambique, with the introduction of ART, the US became the single most 
important player in the AIDS area though US-based organizations such as the Clinton 
Health Access Initiative, the Presidential Emergency Plan for AIDS Relief, US Supply 
Chain Management System, Columbia Diseases Management, and a number of US-
based NGOs dedicated to researching and supplying AIDS treatment. The proliferation 
of AIDS actors and the exponential rise of dedicated funds and project is for anyone 
to see in the country (Pfeiffer et al. 2010). In Zimbabwe AIDS funds and actors have 
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increased too, despite the international community’s condemnation of the country’s 
regime and the consequential limited influx of aid money.  
The renewed interest in drugs and the extra resources brought in by the AIDS epidemic 
to a large extent created a window of opportunity for local producers in the two 
countries by increasing public demand for drugs, and by providing a rationale for 
government intervention to support local production of pharmaceuticals. Ballooning 
drug budgets, compulsory licenses, scrapping of import duties in both countries are 
evidence of the positive dividends accrued to the local pharmaceutical industries by 
the AIDS factor in the two countries. More recently, concerns on the availability of 
ARVs from Asian suppliers, have contributed to creating a sense that African countries 
should build up local manufacturing capacity in order to take full advantage of the 
opportunities offered by compulsory licensing for HIV/AIDS drugs (Owoeye 2014).  
6 Discussion and conclusions 
The analysis of the dynamics of the Mozambican and Zimbabwean pharmaceutical 
manufacturing sectors allows drawing few considerations for the wider debate on local 
production of drugs in Africa. Many of the shortcomings and bottlenecks to local 
production identified by the literature (Wilson, Kohler, and Ovtcharenko 2012) have 
been found in both countries, and are still considered to hamper the development of 
the sector: specialized human resources; uncertain and unfavorable business 
environment adding to local production costs; uncompetitive prices, and limited access 
to international markets. Our analysis has shown how such bottlenecks were 
overcome in the two case studies, either through training locally (Zimbabwe) or abroad 
(Mozambique), procuring goods and services from neighboring countries, or seeking 
access to wider regional markets.  
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As shown in our review of the literature on the subject, despite the persistence of the 
above stumbling blocks, pharmaceutical manufacturing initiatives appear to have 
multiplied across the African continent (see section 2). The experiences of Zimbabwe 
and Mozambique suggest two possible paths for this trend: one based on the pre-
existence of the requisite developmental fundamentals such as Zimbabwe’s strong 
industrial complex and training institutions, and one spurred by the international 
support to drug funding and to setting up Mozambique’s factory. In both cases the role 
of favourable state industrial policies were crucial in issuing compulsory licensing for 
local factories and in finding extra local funds through the AIDS levy in Zimbabwe, and 
in participating directly in set up and management of a public factory in Mozambique. 
It is beyond the scope of this paper to assess whether African pharmaceutical 
manufacturers can be competitive. Our observation of the factories in Mozambique 
and Zimbabwe suggest they may not be able to produce at competitive prices without 
some sort of subsidy or incentive structure, but that a different sort of benefit may be 
at the root of the recent proliferation of similar initiatives across the continent, from 
developing local industrial complex, to strengthening national production for national 
drug security. This is consistent with the findings from a recent study showing that 
albeit not necessarily cheaper, locally produced medicines in Tanzania are more likely 
to be found in rural settings, in comparison to their imported versions, possibly because 
of its reliance on more efficient private sector distribution networks (Mujinja et al. 2014). 
With the end of the TRIPS’ transitional period low and middle-income countries can no 
longer rely on Chinese and Indian manufacturers for a steady supply of cheap drugs 
(Orsi et al. 2007). On the face of this, compulsory licensing and other TRIPS flexibilities 
have become key instruments to securitize drugs provision in LMIC (Nicol and Owoeye 
2013). Although compulsory licensing has only been used sparingly by African 
countries (Beall and Kuhn 2012), and can be issued to a foreign third party, some 
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authors argue that only building local manufacturing capacity would allow African 
countries to take full advantage of the opportunities offered by TRIPS flexibilities 
(Owoeye 2014). Our analysis of the pharmaceutical manufacturing dynamics in 
Mozambique and Zimbabwe suggests that the combination of Africa’s economic 
development, improving industrial conditions, guarantees of support from national 
governments pressing for national drug security, and increased drug funds from the 
international community partly driven by the AIDS epidemic, may be tipping the 
balance and convince manufacturers to enter the business of local pharmaceutical 
production in Africa, despite the persistence of doubts on its short-term profitability and 
viability. 
There is a temptation to extract conclusions from our study on the opportunity for 
African national governments to protect their nascent pharmaceutical manufacturing 
sector. Although some authors have highlighted the positives in the Brazilian domestic 
experience of having a state-owned pharmaceutical industry (Flynn 2008), our study 
fails to provide direct evidence to support the argument that protectionist measures in 
Africa may foster a healthy and competitive local industry, contributing to increase 
population access to drugs. Having a presence in the pharmaceutical market clearly 
appears to give an advantage to the Mozambican and Zimbabwean governments in 
terms of accessing information on production costs and of adapting chemical 
formulations to local epidemiological needs. Nonetheless, whether cash-strapped 
African governments should invest in creating local pharmaceutical manufacturing 
capacity, is still something that needs to be weighed against the competing priorities. 
Some scholars have highlighted how the unresolved tension between public health 
and industrial policy objectives pervades the discourse on local production of drugs, 
meddling the arguments on the subject and polarizing the camp of supporters and 
detractors (Kaplan and Laing 2005; WHO 2011). Some of these tensions were visible 
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in our two case-studies, where advocates of the public health arguments – lining up 
the international health community, local medical organisations, patient protection 
institutions and Ministries of Health – refused to consider the demands from the local 
industry for favourable industrial policies, and the local business community – lining up 
private sector representatives, national business organizations and most national 
governments’ departments – failed to see the importance of extracting the most of 
scant national drug budgets to expand the population’s access to drugs. Some of the 
most recent WHO/UNIDO’s work on the subject goes some way in the direction of 
identifying common grounds for a discussion between the two factions, that should aim 
at guaranteeing minimum outcomes such as: quality standards of locally produced 
drugs, health security of drug supply, selection of essential drugs, affordable prices, 
and innovation for more suitable formulations to local conditions (WHO 2011). But a 
more sustained effort is needed to create a comprehensive framework to incorporate 
the public health and industrial policy views, laying out basic ground rules and 
identifying potential common interests.  
Finally, our study shows that AIDS treatment and ARV production has come to open 
new opportunities to local pharmaceutical production, because of the mobilization of 
extra resources for drugs procurement – particularly in the case of Mozambique - the 
interests it has raised on ARV treatment, and the justification it provided for local 
governments to resort to TRIPS flexibilities for public health purposes, as in the case 
of Zimbabwe’s compulsory licensing experience. Amid concerns that the availability of 
cheap drugs from Asian producers may soon become more circumscribed (Owoeye 
2014), both the Mozambican and Zimbabwean cases demonstrate that such 
opportunities need to be managed by national governments, as the ARV funds made 
available by the international community may not be completely secure in the long-run, 
nor sufficiently flexible to be re-directed from internationally procured drugs to locally-
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produced ones, as the current financing of ARVs public procurement in Mozambique 
eloquently shows. Under these circumstances, investing in the local pharmaceutical 
industry suddenly appears as a sensible option for national governments, while 
diversifying away from the lucrative but volatile ARV business may become a necessity 
for local producers. 
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Tables and figures 
Table 1: Mozambique and Zimbabwe's basic health and healthcare indicators 
Indicator Mozambique Zimbabwe 
Population 25,203,395 13,724,317 
Maternal mortality ratio (per 100,000 live births) 490 570 
Life expectancy at birth  49 56 
<5 mortality (per 1,000 live births) 90 90 
HIV prevalence (15-49) 11.3 14.9 
People living with HIV/AIDS 1,600,000 1,400,000 
Proportion of ART coverage among advanced infections 44 77 
GDP per capita 579 788 
Health expenditures per capita 35 87 
Total HIV/AIDS spending (USD millions)** 144.9 100.5 
Number of pharmacists registered in the country* 447 678 
Pharmaceutical personnel density (per 1000 habitants)* 0.04 0.19 
Currency: 2012 USD unless dif ferent ly stated. Source: The World Bank Database; * Global Health 
Observatory Repository (2008 and 2009 data);  ** UNAIDS 2012 
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Table 2: Public sector drug imports value, by source and type of health programme (2012 USD) 
Health programme and 
associated drugs 
MoH-managed funds* External funds 
(in kind 
donations) 
Total 
Hospital drugs 11,861,471 1,200,883 13,062,354 
Primary care drug kits 8,708,824 0 8,708,824 
Community health 3,870,588 7,217,900 11,088,488 
STD and HIV-SIDA 0 48,750,977 48,750,977 
TB 0 249,550 249,550 
Malaria 0 24,124,599 24,124,599 
Blood banks 967,647 0 967,647 
Oral health 290,294 0 290,294 
Surgical supplies 10,111,912 0 10,111,912 
Laboratory supplies 2,497,000 0 2,497,000 
Imagiology 1,741,765 0 1,741,765 
Total 40,049,500 81,543,908 121,593,408 
Source: CMAM, 2012. * includes both State Budget and PROSAUDE funds 
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Table 3: Public sector drug expenditures, by source of funding (2012 USD) 
Source of funding HIV/AIDS drugs All other drugs Total 
State Budget 0 22,027,225 22,027,225 
PROSAUDE funds 0 18,022,275 18,022,275 
Global Fund 1,742,252 2,315,328 4,057,579 
GDF 0 249,550 249,550 
World Bank  13,846,255 11,260,563 25,106,818 
USAID 27,479,319 11,461,346 38,940,665 
UN (UNFPA and UNICEF) 0 7,506,145 7,506,145 
CHAI 5,683,151 0 5,683,151 
Total 48,750,977 32,792,932 121,593,408 
Source: CMAM, 2012 
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Table 4: Zimbabwe’s imports, exports and trade balance for pharmaceuticals between 2006-2011 
(US$ million at current prices) 
 2006 2007 2008 2009 2010 2011 
Imports  39.2 73.5 77.2 81.1 85.1 89.4 
Exports 1.63 1.15 1.12 1.08 1.05 1.02 
Trade Balance -37.5 -72.4 -76.1 -80.0 -84.1 -88.4 
Source :  Musundire (2012) who compiled the data from UN Comtrade Database DESA/UNSD 
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Table 5: Application of AIDS levy funds across spending categories (2009-2012) 
Application of funds: US$ million 2009 2010 2011 2012 
ARVs 0.89 3.31 10.14 18.60 
Reagents 0 0.44 2.50 1.72 
Kits 0.36 0.59 0.90 0.002 
Equipment 0 2.32 1.97 1.49 
Outreach and Support 0 0.002 1.15 1.01 
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Table 6: Key factors for the development of the pharmaceutical industry Mozambique and 
Zimbabwe 
Type of 
factor 
Mozambique Zimbabwe 
Policy and 
institutional 
Direct involvement international 
agencies in production (Brazilian 
technical cooperation); 
The politics of South-south 
cooperation in generating business 
opportunities through cooperation 
programmes between Brazil and 
Mozambique; 
Existence of a consolidated local 
private pharmaceutical industry (9 
producers) capable of manufacturing 
47% of items in EDL; 
Government direct management of 
production and procurement; 
Low historical dependence on imported 
drugs and capacity to sell to the wide 
region; 
Favourable government regulation 
for local production (equalization 
preference, no import duties for API); 
Favourable government policy and 
regulations (AIDS levy, TRIPS 
flexibility, commitment to buy 75% of 
local output); 
Strong tertiary education sector with 
emphasis on technical training through; 
Strong link between universities, 
polytechnics and industry (Zimdef); 
Economic Sustained economic growth driven 
by the discovery of natural 
resources; 
Zimbabwe’s Industrial development 
trajectory and exclusion from the world.  
Federation market initial impetus for 
local production based on import 
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substitution agenda during sanctions 
and UDI; 
Presence of common fund for drugs 
managed by MoH; 
Government direct funding for the drug 
bill through the AIDS levy as well as 
budgetary allocations; 
Competitive prices thanks to 
subsidies; 
New companies formed by executives 
from existing companies; 
Technological spill-overs; 
Weak private sector demand, 
accounting for less than 15% of the 
market; 
Weak public health demand for drugs 
due to the country’s economic 
downturn.  The private health sector in 
comparison to the public health sector 
is small in Zimbabwe.   
Sustained public sector demand 
supported by international funds. 
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Figure 1: Evolution of major pharmaceutical manufacturing companies in the African continent for selected countries 
 
Source: UNIDO, GIZ and pharmaceutical companies ’ individual websites 
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Annex I – List of pharmaceutical products to be produced by SMM in 
Mozambique 
Type of 
product 
Product name and formulation 
Drippings 
1 Lactate Ringer + AD set 1000 ml injectable 
2 Glucose 1000ml (5%) inj. 
3 Glucose 500 ml (5%) inj.) 
4 Chlorate of Sodium 1000ml (0.9%) inj. 
5 Chlorate of Sodium 500ml (0.9%) inj. 
 Antiretroviral products 
6 Lamivudine 150mg cps.  
7 Ribavirin 250mg cps. 
8 Nevirapina 200mg comprimidos 
9 Lamivudine + Zidovudine + Nevirapine (150+300+200) mg cps  
10 Lamivudine + Zidovudine (150+300) mg cps.  
11 Zidovudine 100mg cps. 
Other solid pharmaceutical compounds 
12 Folic Acid 5mg cps. 
13 Metronidazole 250mg cps 
14 Prednisone 5mg cps 
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15 Prednisone 20mg cps 
16 Glibenclamide 5mg cps 
17 Hydrochlorothiazide 25mg cps 
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